Mobile Edition
Print
Get the Mag
Weekly UpdatesAgennix (Houston) received orphan drug designation for the oral formulation of Talactoferrin alfa (talactoferrin) product. The drug is a treatment for renal cell carcinoma and is currently in phase 2 clinical development.
|
More Resources
|
|||
Orphan drug designation.(FDA Focus: A monthly review of FDA activity, including issuances of approvals, labeling changes, and gu
COPYRIGHT 2006 Medicom International,
Inc. Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company. NOTE: All illustrations and photos have been removed from this article. |
|||
FEED